SCHEMBL2209185

SCHEMBL2209185

Cc1ccccc1N1[CH]CNCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 4/20 0.58
HTR7 P34969 2/20 0.47
HTR3A P46098 5/20 0.44
HTR1A P08908 4/20 0.44
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
ALOX5 P09917 2/20 0.40
LMNA P02545 1/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
DRD2 P14416 1/20 0.38
CYP2C19 P33261 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7438142 0.79 ADRB1 (0.59) ADRB1HTR7HTR3AHTR1ACYP1A2
SCHEMBL2414713 0.79 HTR1A (0.39) ADRB1HTR7HTR3AHTR1AALDH1A1
SCHEMBL3483188 0.78 DRD2 (0.61) ADRB1HTR7HTR3AHTR1ALMNA
SCHEMBL8357275 0.78 EPHX2 (0.44) ADRB1HTR3AHTR1ACYP1A2CYP3A4
SCHEMBL3951003 0.74 SLC6A2 (0.43) ADRB1HTR7HTR3AHTR1ALMNA
SCHEMBL7524539 0.74 ALDH1A1 (0.48) ADRB1HTR3AHTR1ACYP3A4CYP2D6
SCHEMBL4896 0.73 ADRB1 (1.00) ADRB1HTR7HTR3AHTR1ACYP1A2
SCHEMBL29432760 0.73 ADRB1 (1.00) ADRB1HTR7HTR3AHTR1ACYP1A2
SCHEMBL2209183 0.73 ADRB1 (1.00) ADRB1HTR7HTR3AHTR1ACYP1A2
SCHEMBL739058 0.73 SIGMAR1 (0.52) ADRB1HTR7HTR3AHTR1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550093-B2 Third generation taxoids and methods of using same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-02-04 US disclosed
US-20180194744-A1 Third Generation Taxoids and Methods of Using Same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2018-07-12 US disclosed
US-7981926-B2 Fluorotaxoids RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2011-07-19 US disclosed
US-20090118355-A1 Fluorotaxoids RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2009-05-07 US disclosed
EP-2016065-A2 1-(BENZO[D][1,3]DIOXOL-5-YL)-N-(PHENYL)CYCLOPROPANE-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR THE TREATMENT OF CYSTIC FIBROSIS Vertex Pharmaceuticals Incorporated (US) 2009-01-21 EP disclosed
WO-2007087066-A2 1-(BENZO [D] [1,3] DI0X0L-5-YL) -N- (PHENYL) CYCLOPROPANE- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR THE TREATMENT OF CYSTIC FIBROSIS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118355-A1 Fluorotaxoids FAU, ARF5, ARFGEF1 ADRB1 3204/4885HTR7 3804/4885HTR3A 1590/4885
US-20180194744-A1 Third Generation Taxoids and Methods of Using Same CBR3, TUBB3, CBX3 ADRB1 1355/4885HTR7 2722/4885HTR3A 365/4885
US-10550093-B2 Third generation taxoids and methods of using same CBR3, TUBB3, CBX3 ADRB1 1355/4885HTR7 2722/4885HTR3A 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.